Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong

International Journal of Tuberculosis and Lung Disease

Volumn 1, Issue 5, 1997, Pages 411-416

  Tam, C M ^a   Chan, S L ^a   Lam, C W ^b   Dickinson, J M ^c   Mitchison, D A ^c  

^a Chest Services Central Office   (Hong Kong)

^b RUTTONJEE HOSPITAL   (Hong Kong)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Bioavailability; Dosage; Hong kong; Rifapentine

Indexed keywords

DRUG DERIVATIVE; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG DESIGN; DRUG STABILITY; FEMALE; HONG KONG; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DESIGN; DRUG STABILITY; FEMALE; HONG KONG; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 0031241141     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Arioli V, Berti M, Carniti G, Randisi E, Rossi E, Scotti R. Antibacterial activity of DL473, a new semisynthetic rifamycin derivative. J Antibiot 1981; 34: 1026-1032.
2. Mitchison D A, Ellard G A, Grasset J. New antibacterial drugs for the treatment of mycobacterial disease in man. Br Med Bull 1988; 44: 757-774.
3. Truffot-Pernot C, Grosset J, Bismuth R, Lecoeur H. Activity of intermittent rifampicin and cyclopentylrifamycin (DL473) in experimental murine tuberculosis. Rev Fr Mal Respir 1983; 11: 875-882.
4. Dhillon J, Dickinson J M, Guy J A, Ng T K, Mitchison D A. Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis. Tubercle Lung Dis 1992; 73: 116-123.
5. Merrell Dow Research Institute. Rifapentine MDL473: Summary of product characteristics. Lepetit Centre, Gerenzano, Italy. January, 1988.
6. National Co-ordinating Group for Clinical Study of DL473. Controlled clinical trial of cyclopentyl rifamycin in treatment for pulmonary tuberculosis. Chin J Antibiot 1987; 12(5): 321-328.
7. National Co-ordinating Group for Clinical Study of DL473. A controlled clinical trial of DL473-containing chemotherapy regimens for bacillary tuberculosis - results at three years. Chin J Antibiot 1992; 17(5): 322-332.
8. Chan S L, Yew W W, Porter J H D, et al. Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals. Int J Antimicrob Agents 1994; 3: 267-274.
9. R & D Report, DRC 364. Rifapentine: bioavailability of film-coated tablets, suspension and solution after a standard meal. Lepetit Research Centre, Gerenzano, Italy. January 1988.
10. Dickinson J M, Aber V R, Allen B W, Ellard G A, Mitchison D A. Assay of rifampicin in serum. J Clin Pathol 1974; 27: 457-462.
11. Dean A G, Dean J A, Coulombier D, et al. Epi Info, Version 6: a word processing, database, and statistics program for epidemiology on microcomputers. Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 1994.